Mechanisms of Insulin Signaling as a Potential Therapeutic Method in Intestinal Diseases DOI Creative Commons
Sara Jarmakiewicz-Czaja, Aneta Sokal, Katarzyna Ferenc

et al.

Cells, Journal Year: 2024, Volume and Issue: 13(22), P. 1879 - 1879

Published: Nov. 14, 2024

Gastrointestinal diseases are becoming a growing public health problem. One of them is inflammatory bowel disease (IBD), which includes ulcerative colitis (UC) and Crohn’s (CD). The incidence IBD increasing in developing countries declining developed countries, affecting people all ages. Researchers have been exploring new treatment options including insulin signaling pathways the inflammation gastrointestinal tract. It seems that better understanding mechanism IGF-1, GLP-1 TL1A on gut microbiota may provide advances future therapeutic strategies for patients with IBD, but also other intestinal diseases. This review aims to synthesize insights into effects GLP, IGF anti-TL1A microbiota, enable their use therapy

Language: Английский

To establish a new quality assessment method based on the regulation of intestinal microbiota in type 2 diabetes by lignans of Schisandra chinensis (Turcz.) Baill. DOI
Liqiang Shi, Yutong Wang, Yunhui Guan

et al.

Journal of Ethnopharmacology, Journal Year: 2025, Volume and Issue: 348, P. 119822 - 119822

Published: April 16, 2025

Language: Английский

Citations

0
Mechanisms of Insulin Signaling as a Potential Therapeutic Method in Intestinal Diseases DOI Creative Commons
Sara Jarmakiewicz-Czaja, Aneta Sokal, Katarzyna Ferenc

et al.

Cells, Journal Year: 2024, Volume and Issue: 13(22), P. 1879 - 1879

Published: Nov. 14, 2024

Gastrointestinal diseases are becoming a growing public health problem. One of them is inflammatory bowel disease (IBD), which includes ulcerative colitis (UC) and Crohn’s (CD). The incidence IBD increasing in developing countries declining developed countries, affecting people all ages. Researchers have been exploring new treatment options including insulin signaling pathways the inflammation gastrointestinal tract. It seems that better understanding mechanism IGF-1, GLP-1 TL1A on gut microbiota may provide advances future therapeutic strategies for patients with IBD, but also other intestinal diseases. This review aims to synthesize insights into effects GLP, IGF anti-TL1A microbiota, enable their use therapy

Language: Английский

Citations

0